259 filings
Page 6 of 13
DEFA14A
2pc bo54ngd318
29 Apr 20
Additional proxy soliciting materials
7:32am
8-K
4j6ig6s
7 Apr 20
Sage Therapeutics Announces Restructuring to Advance Corporate Strategy and Pipeline
4:25pm
8-K
7zeud1x5 9810b50unw
18 Mar 20
Sage Therapeutics Announces Development Plan for Zuranolone(SAGE-217) Following
6:57am
S-8
5s5yjtuqdr0 ws5
27 Feb 20
Registration of securities for employees
7:32am
8-K
8phsrdse8faxud8l84cp
27 Feb 20
Sage Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
2qwxl29cz250pbexe
5 Dec 19
Sage Therapeutics Reports Topline Results from Pivotal Phase 3
7:01am
8-K
d43u9xb
12 Nov 19
Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights
6:44am
8-K
bkkmn9w xzm6
6 Aug 19
Results of Operations and Financial Condition
7:04am
8-K
c6y21vx 7mz0sm
24 Jul 19
Sage Therapeutics Announces Clinical Updates and Progress Across Neuroscience Pipeline
7:18am
8-K
wj1oy03t7l0
14 Jun 19
Sage Therapeutics Announces U.S. Drug Enforcement Administration Scheduling of ZULRESSOâ„¢ (brexanolone) Injection
9:03am
8-K
ulgv1b8n4vwnw7cv07j
6 Jun 19
Submission of Matters to a Vote of Security Holders
4:36pm
8-K
13ybq8 vmus3u5avfct
2 May 19
Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
7:25am
DEFA14A
tsnb452dx80e do
25 Apr 19
Additional proxy soliciting materials
4:04pm